GLYC OBI
Live / Registered — Registered (as of 19 Aug 2025)
What this means for you
Registered since 19 Aug 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98289547
- Registration number
- 7896178
- Mark type
- Design + words
- Filed
- 29 Nov 2023
- Published for opposition
- 01 Jul 2025
- Registered
- 19 Aug 2025
- Attorney of record
- Ran He
Goods and services
- Class 001 — Chemicals: Carbide; Cellulose; Glycogen; Glycoprotein; Sulfides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Adjuvants, other than for medical or veterinary purposes; Antioxidants for use in the manufacture of pharmaceuticals; Biochemical catalysts; Biological preparations for use in industry and science; Carbonic hydrates; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Fatty acids for use in pharmaceutical; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of drugs
- Class 005 — Pharmaceuticals: Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents
- Class 042 — Scientific and technological services: Biological research; Biological research and analysis; Chemical analysis; Chemical research; Chemical research and analysis; Chemical research services; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research; Medical research in the field of oncology; Medical research services; Medical research services in the field of cancer; Pharmaceutical research and development; Providing information about medical research in the field of cancer, oncology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research in the field of genetics; Technical research in the field of pharmaceutical studies
- Class 044 — Medical, beauty and agricultural services: Administering vaccines to patients; Alternative medicine services; Cancer screening services; Cultured cell bank services for medical transplantation; Health care; Health care services for treating cancer; Health assessment services; Health counselling; Human tissue bank services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical assistance; Medical screening; Medical treatment using cultured cells; Nursing, medical; Occupational therapy; Providing health information in the field of cancer prevention and treatment; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Regenerative medicine services; Remote monitoring of medical data for medical diagnosis and treatment; Telemedicine services
Owner
- OBI PHARMA, INC., Taipei City, TW
- OBI PHARMA, INC., Taipei City, TW
- OBI PHARMA, INC., Taipei City, TW
Prosecution history
- 19 Aug 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 19 Aug 2025 — REGISTERED-PRINCIPAL REGISTER
- 01 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jul 2025 — PUBLISHED FOR OPPOSITION
- 25 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Feb 2025 — CASE RETURNED TO EXAMINATION
- 14 Feb 2025 — NOTICE OF ALLOWANCE CANCELLED
- 14 Feb 2025 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 14 Feb 2025 — PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
- 13 Feb 2025 — ASSIGNED TO PETITION STAFF
- 03 Jan 2025 — TEAS PETITION TO AMEND BASIS RECEIVED
- 01 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 Aug 2024 — PUBLISHED FOR OPPOSITION
- 17 Jul 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED